Valeant Pharma sees FY2016 EPS of $6.60-$7.00, versus prior guidance of $8.50-$9.50 and the consensus of $8.47. Valeant Pharma sees FY2016 revenue of $9.9-10.1 billion, versus prior guidance of $11.0-11.2 billion and the consensus of $10.86 billion.
it dropped from 125$ to 28$ in the months prior to releasing these numbers from ealrier highs of 250$
Feedback is allways appreciated, as are other (annotated) picks Twitter: @RTNRTN To follow on ihub: Ihub mark
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.